This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer ...
4d
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as ...
Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...
We recently published a list of Jim Cramer’s Latest Portfolio: Top 9 Stocks to Buy and Sell. Since Pfizer Inc. (NYSE:PFE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback